Search

Your search keyword '"CCA - Target Discovery ' showing total 285 results

Search Constraints

Start Over You searched for: Author "CCA - Target Discovery Remove constraint Author: "CCA - Target Discovery
285 results on '"CCA - Target Discovery '

Search Results

1. Bortezomib before and after high-dose therapy in myeloma

2. A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer

3. Feasibility of cell-free circulating tumor DNA testing for lung cancer

4. Role of the tumor stroma in resistance to anti-angiogenic therapy

5. Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression

6. Targetable genetic features of primary testicular and primary central nervous system lymphomas

7. Applications of molecular diagnostics for personalized treatment of head and neck cancer: state of the art

8. Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237)

9. Anti-angiogenic properties of chlorambucil derivatives with fluorous and hydrocarbon appendages

10. Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data

11. An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups

12. High-Throughput Firefly Luciferase Reporter Assays

13. Position statement on radiopharmaceutical production for clinical trials

14. Objective smartphone measurements of physical activity and fitness in patients with cancer

15. Effect of magnesium treatment and glucose levels on delayed cerebral ischemia in patients with subarachnoid hemorrhage

16. Spinal cord stimulation as adjuvant during chemotherapy and reirradiation treatment of recurrent high-grade gliomas

17. Influence of health insurance status on paediatric non-Hodgkin's lymphoma treatment in Kenya

18. Time intervals from aneurysmal subarachnoid hemorrhage to treatment and factors contributing to delay

19. Better to be alone than in bad company:The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

20. A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1

21. Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX-3117 into DNA

22. hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients

23. The role of pharmacogenetics in capecitabine efficacy and toxicity

24. Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer

25. Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer

28. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma

29. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter

30. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3

31. On the pharmacogenetics of non-small cell lung cancer treatment

32. Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR

33. Optimization of drug combinations using Feedback System Control

35. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

36. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

39. Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model

41. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

42. Targeting Serglycin Prevents Metastasis in Murine Mammary Carcinoma

44. Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer

45. Using RNA-sequencing to detect novel splice variants related to drug resistance in in vitro cancer models

46. Valproate in adjuvant glioblastoma treatment

47. Contemporary reviews on cancer treatment INTRODUCTION

48. Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors

49. Advances in purine and pyrimidine metabolism in health and diseases

50. Recent developments in the use of immunotherapy in non-small cell lung cancer

Catalog

Books, media, physical & digital resources